RANI THERAPEUTICS HOLDINGS-A (RANI) Stock News

Thursday's session: gap up and gap down stocks

Traders are paying attention to the gapping stocks in Thursday's session. Let's dive into which stocks are experiencing notable gaps.

Which stocks are moving before the opening bell on Thursday?

As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Why Coherent Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket

These stocks are moving in today's after hours session

After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update

- Completed two equity offerings with total gross proceeds of approximately $20.0 million; cash runway extended into 3Q 2025 - - Announced new...

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants

SAN JOSE, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage...

Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit

SAN JOSE, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) --  Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage...

Rani Therapeutics to Participate in September Investor Conferences

SAN JOSE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage...

Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update

- Announced partnership with ProGen on development of RT-114, an oral GLP-1/GLP-2 dual agonist for the treatment of obesity - - Phase 1 study for RT-114...

Rani Therapeutics to Participate in August Investor Conferences

SAN JOSE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage...

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering

SAN JOSE, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage...

Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment

~ New RT-114 obesity program combines ProGen’s FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to...

Rani Therapeutics to Participate in May Investor Conferences

SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage...

Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024

SAN JOSE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage...

RANI Stock Earnings: Rani Therapeutics Hldgs Beats EPS for Q1 2024

RANI stock results show that Rani Therapeutics Hldgs beat analyst estimates for earnings per share the first quarter of 2024.

RANI Stock Earnings: Rani Therapeutics Hldgs Beats EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rani Therapeutics Hldgs (NASDAQ:RANI) just reported results for the first quart...

Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update

- Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Initiation of Phase 2 clinical trial for...

RANI Stock Earnings: Rani Therapeutics Hldgs Beats EPS for Q4 2023

RANI stock results show that Rani Therapeutics Hldgs beat analyst estimates for earnings per share the fourth quarter of 2023.

RANI Stock Earnings: Rani Therapeutics Hldgs Beats EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rani Therapeutics Hldgs (NASDAQ:RANI) just reported results for the fourth quar...

Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update

- Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Announced Preclinical...

Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

SAN JOSE, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage...

Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist

- Transenteric delivery of incretin triagonist of GLP-1, GIP, glucagon receptors elicits rapid weight loss in animal study – - Preclinical data...